




2026 Q3 | CONFIDENTIAL

DiaGen AI

Tech-Bio Partnering: Tools and Deployment

Validated AI Platforms/Tools for rapidly identifying small molecules and peptides.

Deployed through clinical, academic, commercial and decentralized partners to scale revenue & impact patients

2

Validated
AI platforms

4

Regions:
NA / EU / MENA / APAC

7

Active Partnerships

Our Mission

Design: Peptide & Small Molecules

Innovate: Modalities for Diagnostics

Apply: Globally to Patients

One AI engine, two protocols, driving internal asset development & service SME's

RX

THERAPEUTICS

Designing the peptide medicine

AI therapeutics: bespoke generative models, structural prediction and active-learning cycles that break the stability and delivery bottlenecks.

1 Generative Design & Target Binding

- De novo generation: protein language models (ESM2), diffusion models and physics-informed modeling build candidate sequences from scratch.
- Structure prediction: docking and mapping peptide interactions against complex pockets and targets.

2 Property Optimization & Modification

- ADMET profiling: screening for the toxicity, solubility and permeability barriers common to therapeutic peptides.
- Chemical enhancement: non-natural amino acids, cyclization and stapling designed in to resist proteolysis.

3 Closed-Loop Validation (DMTA Cycle)

- Active learning: computational models retrained on ground-truth data from high-throughput biochemical and cellular assays.

DX

DIAGNOSTICS (Focus on Longevity)

Creating the detection tools for diagnostics

AI diagnostics: custom peptide binding probes paired with machine learning models to detect disease biomarkers with high precision.

1 Computational Design & Screening

- Generative models: transformers and diffusion architectures design novel peptides that bind disease-related proteins and antibodies.
- In silico binding affinity: thousands of candidate sequences screened virtually to isolate the tightest fit for pathological markers.
- Structure prediction: ML maps 3D peptide conformations to ensure structural stability in biological fluids.

2 Detection & Signal Amplification

- Reporter coupling: optimized peptides fused with fluorescent, bioluminescent or radioisotope markers to tag target cells.
- Nanotechnology integration: labelled peptides anchored to nanoparticles to multiply signal readout in PET and MRI imaging.
- Multiplexed profiling: ML reads binding patterns across peptide microarrays to diagnose or track response from one sample.

Two Validated AI Protocols

BLACKCOMB Protocol

Small Molecule Platform

- Molecule optimization and acceleration
- Atomic-resolution foundation model trained on 500 million molecules.
- Flow-network generative architecture, physics-informed
- Explores adjacent chemical space around lead / patent compounds to produce novel, patentable analogs

Validated: KRAS-G12D degradation confirmed in cells by the Structural Genomics Consortium

CYPRESS Protocol

Peptide Platform

- Peptide research efficacy and precision
- Identifies the most effective binder from billions of candidates
- End-to-end in silico pipeline: hotspot ID → backbone → sequence → MD validation
- Materially lower compute demand than conventional screening

Validated: designed 30-mer holds a stable complex with C-reactive protein across a 100-ns MD simulation

Both platforms are in active partner deployment — not internal-only research.

Expanding Partnerships & Status

PARTNER	ROLE	PLATFORM / ASSET	STATUS
Hadassah — Hadasit / Ariel Univ.	Peptide & Radio Pharma co-development	Three projects toward commercialization	Signed
UNC — Structural Genomics Consortium	Wet-lab validation, open science	KRAS oncology catalog (DGEN1-5)	Signed
Mila — Quebec AI Institute	Government-supported research	Protein design support at scale	Signed
University Lab (Ongoing Negotiations)	Biosensor assets co-development	CRP biosensor for longevity	Under NDA
AKT Health	Advisory, clinical and global expansion	APAC and MENA Pipeline Sales	Advisory + JV
MetaNova Labs	Decentralized discovery & Data	Hit-picking tool, Bittensor SN68	JV LOI
Contango / General Tensor	De-sci compute, subnet dev opp support	Decentralized discovery mining to Earn \$TAO	JV announced

 Executed and in delivery

 Contracting

 Decentralized science

Hadassah — Hadasit / Ariel University

Binding agreement covering three projects toward commercialization.

Hadasit contributes

- Targets and existing datasets
- Peptide synthesis
- In vitro and in vivo validation
- Lead commercialization role

DiaGen contributes

- Novel peptide candidates from CYPRESS
- Generative design and in silico screening
- Multi-objective optimization
- Option to commercialize under ROFR

IP & ECONOMICS

- Each party retains its background IP
- New IP owned by Hadasit / Ariel
- DiaGen shares downstream revenue on milestones and royalties w/ a defined ROFR
- Upside without full development cost

STRATEGIC UPSIDE

Platform Validation

AI-designed peptides synthesised and tested in vitro and in vivo by a leading clinical research institution.

Credibility

Engagement with a globally recognised healthcare organisation opens clinical, academic and commercial doors.

Downstream Economics

Milestone and royalty participation tied to molecules DiaGen helped design.

UNC — Structural Genomics Consortium

Nature of the relationship

- Joint AI and wet-lab research collaboration targeting KRAS-driven cancers.
- DiaGen supplies AI-generated peptide and degrader libraries; UNC-SGC leads experimental validation and biological testing under Dr. Alison Axtman.
- Combines generative design with SGC's open-science experimental infrastructure.
- DiaGen retains all rights and IP as the catalog advances.

RESULT TO DATE

Initial degrader molecules perform as expected in cells, degrading mutant KRAS — a target long considered undruggable.

ASSET SNAPSHOT

ASSET

DGEN1-5 KRAS catalog

INDICATION

Pancreatic & Colorectal cancer

STAGE

Pre-clinical

STATUS

Available for partnering

IP

Retained in full by DiaGen

L.I.V.E.

Longevity Informed by Vigorous biomarker Evaluation

First-mover continuous biochemical monitor for aging and longevity.

A minimally invasive, AI-powered wearable that reads consensus aging biomarkers from sweat and interstitial fluid in real time — letting consumers, clinicians, scientists and investors objectively judge whether any anti-aging intervention actually works.

5 weighted aging pillars in the SBAI index

16+ sweat proteins screened for detectability

From an unmeasurable market to a measurable one

THE GAP

- Anti-aging interventions are exploding — with no reliable way to assess impact.
- Assessment today is episodic and invasive (labs, scans, visits) or unreliable (self-report).
- Consensus markers (IGF-1, GDF-15, IL-6, hs-CRP) are rarely run outside research labs.

THE OPENING

- Wearables (Oura \$11B, Whoop \$3.6B) and lab platforms (Function \$2.5B) infer aging indirectly — none measure biochemistry continuously.
- Upside case: FDA disease designation for pathological aging.

SWEAT-BASED BIOLOGICAL AGE INDEX (SBAI)

Inflammation / immune aging	30%	S100A8/A9, S100A7, dermcidin, HSP70
Oxidative & mitochondrial aging	25%	SOD1, catalase, HSP90, LDH
Skin turnover & ECM breakdown	20%	Keratins, elastins, MMP-1, psoriasin
Stress / HPA-axis / circadian	15%	Alpha-amylase, HSP70, SOD1, catalase
Metabolic aging	10%	Ammonia peptides, albumin, urea, lactate

WHY DIAGEN AI

- Bespoke peptide binders designed via CYPRESS
- Conditional sequence design: GFlowNets, protein LLMs, discrete diffusion
- Wearable pedigree: Vitaliti, Qualcomm Tricorder XPRIZE

NEXT STEPS

- Define and protect IP; trademark LIVE
- Build binders; partner academic biosensor labs
- Size TAM; develop for out-licensing or acquisition

University Lab (To be Announced Soon)

Nature of the relationship

- World Renowned domain expert in biosensing to advise
- Post-NDA; scope of work being defined.
- DiaGen designs peptide binders against specific 'healthgeivity' biomarkers.
- Joint development of continuous monitoring device(s) driven by AI.

Foundation publication: Frontiers in Aging (2025) — Biomarker Integration and Biosensor Technologies Enabling AI-Driven Insights into Biological Aging.

WHY IT MATTERS

1

Unmet capability

Existing technologies cannot continuously detect proteins, cytokines and hormones in real time — current systems read small molecules on an episodic basis.

2

DiaGen's contribution

AI-designed peptide binders that selectively recognise target biomarkers, enabling continuous, multiplexed molecular sensing.

3

Commercial shape

A modular biosensor plus AI analytics platform for early disease detection — licensed to diagnostics manufacturers.

AKT Health - Global Market Revenue Expansion



Nature of the relationship

Aditya Tallapragada, President of AKT Health, has joined DiaGen's advisory board — providing guidance on healthcare AI market development, partnerships, capital strategy and global expansion, with boots on the ground across the Pacific Rim and MENA starting in Dubai.

THE BRIDGE

Upstream innovation DiaGen's generative AI for peptides and molecules

+

Downstream execution For AKT's client clinical trials, regulatory pathways and commercialization efforts applying our AI

UPSIDE FOR DIAGEN

1

Global market expansion

AKT's presence in the U.S., Japan, UAE and Singapore opens key APAC and Middle East biopharma markets.

2

Translation to real-world systems

AKT translates innovation into clinical and commercial outcomes, de-risking platform adoption in pharma workflows.

3

Platform + infrastructure synergy

Potential integration of DiaGen's discovery engine with AKT's clinical/commercial AI platforms (e.g. Hakase AI).

4

Shared revenue streams

Joint DiaGen / AKT commercial lines implementing the AI flywheel.

The Future: A Three-Layer Decentralized Science Stack

DiaGen is among the first drug discovery companies to move into blockchain-based decentralized AI. The strategy is materially stronger because each partner occupies a distinct layer of the value chain.



Compute + ECOSYSTEM

Contango Digital Assets / General Tensor

Compute, token strategy, network bootstrapping, distribution



APPLICATION (SCIENCE)

MetaNova Labs

Drug discovery workflows, subnet & tool devs, decentralized data access



BASE LAYER

Bittensor

Incentivized compute, democratization of data, alternative token revenue

Many DeSci efforts lack either real science or real infrastructure. This triad supplies technical legitimacy, infrastructure, and capital together.

MetaNova Labs

Decentralized molecular discovery partner and benchmarking layer.



The relationship

- Crypto-native biotech built directly on Bittensor, operating a decentralized drug screening subnet (SN68).
- Co-development partner on a multi-objective hit-picking tool evaluating small molecules for novelty, affinity and target specificity across multi-million to billion-scale libraries.
- Benchmarking counterparty for DiaGen's generative peptide and small molecule models in an open, incentive-driven environment.
- Shared subnet collaborator — both parties contribute models, validators and datasets.

STRATEGIC UPSIDE

● External validation of model performance

Benchmarking against decentralized competitors introduces market-based validation rather than internal metrics — particularly valuable where ground truth is sparse.

● Access to massive chemical search space

MetaNova explicitly targets huge unexplored chemical space via distributed compute.

● Faster iteration via subnet competition

Incentivized contributors continuously improve scoring, docking and generation models — a dynamic optimization layer around DiaGen's core IP.

● Controlled exposure

Proprietary models stay proprietary; DiaGen benefits from external improvements to adjacent tasks and becomes a canonical workload in decentralized discovery.

Contango Digital Assets / General Tensor



Ecosystem access and decentralized compute enablement.

The relationship

- Web3-native venture and ecosystem builder focused on decentralized AI and blockchain infrastructure, active across 100+ projects.
- CEO Mike Grantis serves as strategic advisor to DiaGen on decentralized initiatives.
- Supports Bittensor subnet participation — validator/miner strategy and token economics.
- Provides compute requirement support across the decentralized AI ecosystem.


\$100K

committed capex toward decentralized compute —
\$40K deployed to date.


STRATEGIC UPSIDE

- **Capital and aligned investors**
A thesis explicitly centred on decentralized AI, establishing DiaGen's presence in the category.
- **Subnet strategy and tokenomics**
Success on Bittensor is not purely technical — it requires incentive alignment and validator relationships.
- **Compute orchestration**
Facilitates the compute required to mine on subnets.
- **Adjacent exposure**
New model architectures, partnerships beyond biotech, and early access to emerging DeAI primitives.

The Closed-Loop Innovation System



EMERGENT ADVANTAGES



Underwriting the flywheel, marketing, sales and royalty model to achieve global scale — leveraging banking, biotech analyst and investor channels.

Historical Recognition & Validation

2025

SELECTED ×2

SCALE AI Top 100 AI Company

SELECTED

VivaTech Paris Delegation

TOP 8 OF 300

“Tech for Change” Recognition

SEMI-FINALIST

Merck Digital Studio Innovation Fund

QUALIFIER

Canadian Entrepreneur in Life Sciences (CELS) Showcase

AWARDED

NVIDIA Inception Program

2024

PARTNER

Mila — Quebec AI Institute

PARTNER

Structural Genomics Consortium

SEMI-FINALIST

SuperNova Challenge

Gitex, Dubai

2023

BACKED BY

Frontier IP Group (LON:FIIP)

4.26% shareholder

GRADUATE + QUALIFIER

Creative Destruction Lab

UW Computational Cohort; CDL Super Cohort, Toronto

11

independent recognitions across AI, healthcare and capital markets in three years.

Recognition spans all three pillars of the business — the AI platform, the science, and the capital structure.

TEAM

Leadership, Operations & Advisors

100+ years of combined experience across AI, ML, drug discovery and capital markets.



Brian D. Keane

CEO, Chairman

26+ yrs in capital markets, \$3B+ transactions.
Ex-advisor/banker at Rodman & Renshaw and Ladenburg
Thalmann. JD, New York Law School.



Paolo Lobo

President / COO

MSc Biochemistry (UBC). 10+ yrs in IVD and biotech across
business development, regulatory strategy and partnerships.
Published in Nature.



Andrew Chan

CFO

Finance and operations leader for early-stage startups.
Former Finance Manager at Electronic Arts; Head of Finance
at Xtract AI.



Eric Baum

Co-Founder / Director

20+ yrs advising Fortune 50 companies. Co-Founder Solidea
Capital, Director Acquis Consulting, SSI Strategy



Mohit Pandey

Chief AI Officer

AI/ML for life sciences, widely published. PhD Bioinformatics
(UBC), MS in CS (Rutgers). Formerly Recursion (Nasdaq:
RXXR) and Weill Cornell.



Noah El Rimawi-Fine

ML Engineer/Advisor

Master's at McGill and Mila researching ML for drug
discovery, biomolecular design and genetics. BSc
Mathematics and Computer Science. Recently Joined J&J



Ivan Semenov

Computational Drug Design

MSc Bioorganic Chemistry (summa cum laude). 4+ yrs in
pharma as a computational chemist. Leads CADD and
AI-driven protein design.



Dr. Sonny Kohli

Director, Chief Medical Advisor

Physician and Faculty at McMaster. Co-founded Cloud DX,
winner of Canada's first XPRIZE for the medical tricorder.
Former CSA astronaut candidate.



Aditya Tallapragada

Advisor

Founder of AKT Health. 15+ yrs in life sciences and clinical
research, applying AI and deeptech to regulatory workflows.
Built Impakt Health, a Japan-certified Class II SaMD.



Mike Grantis

Advisor

7+ yrs investing in liquid tokens and private allocations.
Co-Founder and Managing Partner, Contango Digital Assets
and General Tao Ventures.



Paul Crath

Director / Legal Advisor

Partner and Head of Capital Markets at CMX Law, New York.
30+ yrs in capital markets, M&A and cross-border
transactions. Bar: New York.

11

operators and advisors spanning drug
discovery, machine learning, clinical
regulation and capital markets — across
Canada, the U.S., the UK, EU and UAE.

Cap Structure & Current Financing

CAD \$3.5M Capital raised to date	40% Founder/Insider	60% Retail/Inst/FO	90M Shares Out	165 # of Shareholders	CAD \$40K Average investment
---	-------------------------------	------------------------------	--------------------------	---------------------------------	--

Institutional & Family Office Backing

- Canaccord Genuity
- Haywood Securities
- Research Capital
- Ventum Financial
- Jemini Capital
- Euroswiss Capital
- Carella Capital
- Solidea Capital
- JSTR Group
- Maelstrom Family Office

RRSP & TFSA ELIGIBLE

Non-brokered offering; investors sourced directly and through the platforms above.

\$1m Discount “Bridge to Exit” Offering — Private Placement of Units

Issuer	DiaGen AI Inc., a private, non-reporting issuer formed in British Columbia
Unit	One common share plus one-half of one common share purchase warrant
Issue Price	\$0.07 per Unit
Issue Size	Target maximum of \$1,000,000 gross proceeds, subject to adjustment
Warrants	Each whole warrant exercisable at \$0.25 for three years from closing
Use of Proceeds	Hadassah & General working capital and expenses of a going-public transaction
Finder's Fee	Up to 8% cash and up to 8% broker warrants at \$0.07, 36-month term
Jurisdictions	Canada, U.S. (Reg D Rule 506(b)) and other jurisdictions, per applicable law
Hold Period	Resale restrictions apply and may be indefinite while non-reporting
Closing	August 1st, & 15th or on such date or dates as determined by the Corporation

Summary only — full terms are governed by the subscription agreement and offering documents. The Corporation is a private corporation and is not a reporting issuer in any jurisdiction. There is no market for its securities, nor any assurance that one will develop. As a private corporation it is not subject to the same reporting or corporate governance obligations that exist for reporting issuers. Investors should consider these and other risks inherent in private issuers.

Exit-Ready Pathway

Three routes to a public listing, with the professional bench already retained.

1

ACTIVE

Public Sale to an Existing Nasdaq Company

Currently under NDA, with ongoing negotiations underway with several biotech companies.

2

ALTERNATIVE ROUTE

Reverse Merger

3

ALTERNATIVE ROUTE

Traditional IPO

PROFESSIONAL TEAM IN PLACE

CANADIAN SECURITIES



ACCOUNTING



U.S. GENERAL COUNSEL



CORPORATE LOGISTICS



M&A ADVISOR

To be appointed

Net proceeds of the current offering include expenses relating to a going-public transaction. The Corporation is a limited reporting issuer in Canada, however, no assurance can be given that any listing, merger or sale will be completed.

Why Invest in DiaGen?

1 Third-party Validated Co-Science

SGC confirmed in-cell degradation of mutant KRAS; CYPRESS-designed binders hold stable complexes in MD simulation.

2 Non-Dilutive Development

Academic and institutional partners carry synthesis and wet-lab cost while DiaGen retains or shares IP.

3 Global Commercial Reach

AKT Health opens APAC and MENA; Hadasit leads clinical commercialization in Israel; UNC and Team anchor North America.

4 A Differentiated Data Moat

Decentralized subnets supply chemical search space and market-based benchmarking that centralized competitors do not have.

5 Defined Revenue Pathway

Enterprise tools, catalog sales, milestones and royalties, licensing, and subnet token participation.

DiaGen AI

Tech-Bio Partnerships

Tools and Deployment

Thank You

Brian D. Keane, JD · Chairman, DiaGen AI

- www.DiaGen.AI
- brian@DiaGen.AI

This document is confidential and provided for information purposes only. It contains forward-looking statements subject to known and unknown risks and uncertainties; actual results may differ materially. All financial information is unaudited. Refer to the full forward-looking statements and provincial disclaimers accompanying the DiaGen AI corporate presentation.

DiaGen in the News

Announced milestones, December 2023 to date.

Jun 18, 2026 Collaboration & Revenue Share Agreement with Hadassah Medical Organization and Ariel University

Mar 12, 2026 Life sciences and AI expert Aditya Tallapragada appointed to the Advisory Board

Nov 25, 2025 Study published: Biomarker Integration and Biosensor Tech Enabling AI-Driven Insights in Biological Aging

Sep 16, 2025 Chosen again as a Top 100 Canadian Tech Company, exhibiting at ALL IN AI Montreal

May 23, 2025 JV with Contango Labs to launch its first decentralized drug discovery miner on Bittensor \$TAO

Nov 7, 2024 Partnership with Mila to scale protein design in diagnostics and drug discovery

Jun 27, 2024 Research collaboration with the Structural Genomics Consortium at UNC Chapel Hill

May 2, 2024 Frontier IP announces stake in DiaGen AI and the TVG collaboration

Mar 6, 2024 Unit financing and appointment of Davidson & Company LLP as independent auditor

Jan 30, 2024 Partnership with Cambridge, UK-based The Vaccine Group (TVG) to co-develop novel vaccines

Dec 13, 2023 Proteic Biosciences Inc. renamed DiaGen AI Inc. — new CEO, new website and corporate update

Platform Demo



WHAT THE DEMO COVERS

1

Objective setup

Selecting and weighting property objectives — MW, LogP, QED and custom targets.

2

Generation

Flow-network sampling of candidates against the weighted objective profile.

3

Visualization

2D and 3D structures, docking poses and interaction analysis in one view.

4

Iteration

Similarity-to-seed control and iteration count for adjacent chemical space.

<https://youtu.be/sq3LtyU7Qdk>

Publications (Sample)

Peer-reviewed and preprint work from the DiaGen team and its scientific founders.

Biomarker Integration and Biosensor Technologies Enabling AI-Driven Insights into Biological Aging

Jared A. Kushner, Mohit Pandey, Sandeep (Sonny) S. Kohli

DiaGen AI, Vancouver, British Columbia · Frontiers in Aging (2025)

Why Pool When You Can Flow? Active Learning with GFlowNets

Renfei Zhang, Mohit Pandey, Artem Cherkasov, Martin Ester

Simon Fraser University · Vancouver Prostate Centre · UBC Faculty of Medicine · DiaGen AI

Protein Design Using Physics Informed Neural Networks

Sara Ibrahim Omar, Chen Keasar, Ariel J. Ben-Sasson, Eldad Haber

Proteic Bioscience Inc., Vancouver, British Columbia

Mimetic Neural Networks: A Unified Framework for Protein Design and Folding

Moshe Eliasof, Tue Boesen, Eldad Haber, Chen Keasar, Eran Treister

Protein design and folding methodology

Mohit Pandey — full body of work: scholar.google.com/citations?user=oUhThscAAAAJ